Drugs / EMUNKITUG
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05238883 | Mar 2022 → Dec 2026 expected | cervical cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma +5 | HiFiBiO Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMUNKITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068246 ↗ |
| Known as | HFB200301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238883 ↗ |
| Action | Activate | “HFB200301 (TNFR2 Agonist Antibody)” NCT05238883 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068246 ↗ |
| Route | Intravenous | “Participants will be administered HFB200301 at dose levels 1-5 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).” NCT05238883 ↗ |